Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Stock Has Average Target Price of $110.91 According to Analysts

Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the fifteen brokerages that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have issued a buy rating and two have issued a strong buy rating on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $110.91.

GPCR has been the topic of several recent analyst reports. HC Wainwright reiterated a “buy” rating on shares of Structure Therapeutics in a report on Thursday, November 12th. Weiss Ratings raised shares of Structure Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, November 4th. Citigroup restated a “market outperform” rating on shares of Structure Therapeutics in a report on Friday, August 7th. Wall Street Zen cut shares of Structure Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, October 3rd. Finally, Citizens Jmp reaffirmed a “market outperform” rating and issued a $110.00 target price on shares of Structure Therapeutics in a research report on Wednesday, September 9th.

View Our Latest Analysis on GPCR

Structure Therapeutics Stock Performance

NASDAQ GPCR opened at $16.14 on Friday. The stock has a market cap of $1.13 billion, a P/E ratio of -12.51 and a beta of -1.12. Structure Therapeutics has a fifty-two week low of $16.06 and a fifty-two week high of $94.90. The stock has a 50 day simple moving average of $25.49 and a two-hundred day simple moving average of $44.30.

Structure Therapeutics (NASDAQ:GPCR – Get Free Report) last posted its earnings results on Monday, November 9th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.15). Sell-side analysts predict that Structure Therapeutics will post -2.14 earnings per share for the current year.

Hedge Funds Weigh In On Structure Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. IFP Advisors Inc purchased a new stake in Structure Therapeutics in the second quarter worth about $46,000. Sterling Capital Management LLC grew its holdings in shares of Structure Therapeutics by 63.6% during the 3rd quarter. Sterling Capital Management LLC now owns 3,345 shares of the company’s stock worth $105,000 after acquiring an additional 1,300 shares during the period. Assetmark Inc. raised its position in shares of Structure Therapeutics by 21.4% in the 1st quarter. Assetmark Inc. now owns 2,544 shares of the company’s stock worth $123,000 after acquiring an additional 449 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Structure Therapeutics in the 3rd quarter worth approximately $132,000. Finally, Parallel Advisors LLC raised its position in shares of Structure Therapeutics by 12.7% in the 3rd quarter. Parallel Advisors LLC now owns 8,286 shares of the company’s stock worth $259,000 after acquiring an additional 934 shares in the last quarter. 91.78% of the stock is owned by institutional investors.

Structure Therapeutics Company Profile

(Get Free Report)

Structure Therapeutics is a clinical-stage biopharmaceutical company developing medicines for metabolic and other chronic diseases. Its research approach uses structural biology and computational methods to identify and design small-molecule drug candidates. The company’s pipeline includes aleniglipron, an oral small-molecule GLP-1 receptor agonist being developed for obesity and related metabolic conditions. Structure Therapeutics is also advancing other drug candidates targeting biological pathways associated with metabolic disease.

See Also

Analyst Recommendations for Structure Therapeutics (NASDAQ:GPCR)

Receive News & Ratings for Structure Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Structure Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.